Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database Analysis
- PMID: 34335076
- PMCID: PMC8324372
- DOI: 10.1155/2021/9976122
Patterns of Perioperative Treatment and Survival of Localized, Resected, Intermediate- or High-Grade Soft Tissue Sarcoma: A 2000-2017 Netherlands Cancer Registry Database Analysis
Abstract
Background: Standard therapy for localized soft tissue sarcoma (STS) is wide, limb-sparing resection. For intermediate- or high-grade tumors, (neo)adjuvant therapies are frequently added to the treatment plan. In this study, data from a Dutch nationwide database are used to (1) assess whether perioperative management of STS follows ESMO guidelines, (2) characterize prognostic factors for overall survival (OS), and (3) assess the association between perioperative treatment and survival.
Methods: All intermediate- or high-grade, localized STS cases, who have undergone surgery and diagnosed between 2000 and 2017, were identified in the Netherlands Cancer Registry (NCR) database. Variables with demographic, treatment, and survival data were obtained. Survival curves were estimated by Kaplan-Meier's method, and the effect of prognostic factors on OS was assessed in a multivariable Cox regression analysis.
Results: A total of 4957 patients were identified. There were slightly more males (54.7%). Median age at diagnosis was 64 years, and 53.6% of the tumors were located in the extremities. Radiotherapy (RT) was administered to 2481 (50.1%) patients, and 252 (5.1%) patients were treated with perioperative systemic chemotherapy. The total use of perioperative RT did not significantly change in the last 20 years, but the timing followed clinical guidelines: preoperative RT increased significantly (2000-2008: 3.7%, 2009-2017: 22.3%; p < 0.001), whereas the use of postoperative RT diminished (2000-2008: 45.9%, 2009-2017: 26.1%; p < 0.001). The use of perioperative chemotherapy slightly decreased (2000-2008: 5.9%, 2009-2017: 4.4%; p = 0.015). 5-year OS was 59.6% (95% CI: 58.2-61.0). Sex, age, year of diagnosis, tumor location, tumor size, histological grade, depth, histological subtype, surgical margins, and the use of perioperative RT were identified as independent predictors for OS.
Conclusion: Preoperative RT is gradually replacing postoperative RT for localized STS in the Netherlands. The use of perioperative chemotherapy is rare and has slightly decreased in recent years. Identified baseline characteristics and treatment factors predicting OS may aid in future treatment decisions.
Copyright © 2021 Milan Van Meekeren et al.
Conflict of interest statement
The authors declare that there are no conflicts of interest regarding the publication of this paper.
Figures



Similar articles
-
The role of neoadjuvant radiochemotherapy in the management of localized high-grade soft tissue sarcoma.Radiat Oncol. 2022 Aug 8;17(1):139. doi: 10.1186/s13014-022-02106-2. Radiat Oncol. 2022. PMID: 35941656 Free PMC article.
-
Neoadjuvant Radiotherapy is Associated with R0 Resection and Improved Survival for Patients with Extremity Soft Tissue Sarcoma Undergoing Surgery: A National Cancer Database Analysis.Ann Surg Oncol. 2017 Oct;24(11):3252-3263. doi: 10.1245/s10434-017-6019-8. Epub 2017 Jul 24. Ann Surg Oncol. 2017. PMID: 28741123 Free PMC article.
-
Preoperative vs postoperative radiation therapy in localized soft tissue sarcoma: Nationwide patterns of care and trends in utilization.Pract Radiat Oncol. 2017 Nov-Dec;7(6):e507-e516. doi: 10.1016/j.prro.2017.04.010. Epub 2017 Apr 18. Pract Radiat Oncol. 2017. PMID: 28551391 Free PMC article.
-
Treating soft tissue sarcomas with adjuvant chemotherapy.Curr Treat Options Oncol. 2011 Mar;12(1):21-31. doi: 10.1007/s11864-011-0145-5. Curr Treat Options Oncol. 2011. PMID: 21384115 Review.
-
Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey.Oncologist. 2018 Apr;23(4):461-467. doi: 10.1634/theoncologist.2017-0391. Epub 2017 Nov 30. Oncologist. 2018. PMID: 29192019 Free PMC article. Review.
Cited by
-
Prediction tools for the personalized management of soft-tissue sarcomas of the extremity.Bone Joint J. 2022 Sep;104-B(9):1011-1016. doi: 10.1302/0301-620X.104B9.BJJ-2022-0647. Bone Joint J. 2022. PMID: 36047022 Free PMC article. Review.
-
Long-term survival of participants in the PASART-1 and PASART-2 trials of neo-adjuvant pazopanib and radiotherapy in soft tissue sarcoma.Acta Oncol. 2025 Jan 15;64:69-77. doi: 10.2340/1651-226X.2025.42333. Acta Oncol. 2025. PMID: 39813174 Free PMC article.
-
New trends in the surgical management of soft tissue sarcoma: The role of preoperative biopsy.World J Clin Oncol. 2023 Feb 24;14(2):89-98. doi: 10.5306/wjco.v14.i2.89. World J Clin Oncol. 2023. PMID: 36908679 Free PMC article. Review.
-
Preoperative radiotherapy combined with surgery versus surgery alone for primary retroperitoneal sarcoma: a meta-analysis.Sci Rep. 2025 Jan 8;15(1):1345. doi: 10.1038/s41598-024-84636-1. Sci Rep. 2025. PMID: 39779764 Free PMC article.
References
-
- WHO Classification of Tumours Editorial Board. WHO Classification of Tumours of Soft Tissue and Bone. 5th. Lyon, France: IARC Press; 2020.
-
- PDQ Adult Treatment Editorial Board. PDQ Cancer Information Summaries. Bethesda, MD, USA: National Cancer Institute (US); 2002. Adult soft tissue sarcoma treatment (PDQ®) https://www.ncbi.nlm.nih.gov/books/NBK66046/
-
- Casali P. G., Abecassis N., Aro H. T., et al. Soft tissue and visceral sarcomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Annals of Oncology: Official Journal of the European Society for Medical Oncology. 2018;29(Suppl 4):iv51–iv67. doi: 10.1093/annonc/mdy096. - DOI - PubMed
-
- Von Mehren M., Kane J. M., Bui M. M., et al. Clinical Practice Guidelines in Oncology. PA, USA: NCCN; 2020. Soft tissue sarcoma. https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf.
LinkOut - more resources
Full Text Sources